General aspects of anti-arrhythmic treatment with aprindine.
D000284:Administration, Oral; D000814:Aniline Compounds; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy; D001282:Atrial Flutter / Q000188:drug therapy; D005117:Cardiac Complexes, Premature / Q000188:drug therapy / Q000503:physiopathology; D004048:Diethylamines; D006261:Headache / Q000139:chemically induced; D006325:Heart Atria / Q000503:physiopathology; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007192:Indenes / Q000627:therapeutic use*; D007275:Injections, Intravenous; D013610:Tachycardia / Q000188:drug therapy / Q000503:physiopathology; D014202:Tremor / Q000139:chemically induced; D014717:Vertigo / Q000139:chemically induced; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy / Q000503:physiopathology
D000814:Aniline Compounds; D000889:Anti-Arrhythmia Agents; D004048:Diethylamines; D007189:Indans; D007192:Indenes